{
    "xml": "<topic id=\"PHP5315\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/epirubicin-hydrochloride\" basename=\"epirubicin-hydrochloride\" title=\"EPIRUBICIN HYDROCHLORIDE\">\n<title>EPIRUBICIN HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1030\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antibiotics-cytotoxic/epirubicin\">Epirubicin</xref>\n</p>\n<data name=\"vtmid\">349848009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_109608734\" title=\"Anthracyclines\">Anthracyclines</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP49782\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/epirubicin-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of breast cancer</p>\n<p outputclass=\"therapeuticIndication\">Treatment and prophylaxis of certain forms of superficial bladder cancer</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion or by intravesical instillation</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49849\" outputclass=\"contraindications\" rev=\"1.30\" parent=\"/drugs/epirubicin-hydrochloride\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Bladder inflammation or contraction (when used as a bladder instillation)</ph>; <ph outputclass=\"contraindication\">catheterisation difficulties (when used as a bladder instillation)</ph>; <ph outputclass=\"contraindication\">haematuria (when used as a bladder instillation)</ph>; <ph outputclass=\"contraindication\">invasive tumours penetrating the bladder (when used as a bladder instillation)</ph>; <ph outputclass=\"contraindication\">myocardiopathy</ph>; <ph outputclass=\"contraindication\">previous treatment with maximum cumulative doses of epirubicin or other anthracycline</ph>; <ph outputclass=\"contraindication\">recent myocardial infarction</ph>; <ph outputclass=\"contraindication\">severe arrhythmia</ph>; <ph outputclass=\"contraindication\">severe myocardial insufficiency</ph>; <ph outputclass=\"contraindication\">unstable angina</ph>; <ph outputclass=\"contraindication\">urinary tract infections (when used as a bladder instillation)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49885\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/epirubicin-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Caution in handling&#8212;irritant to tissues</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49774\" outputclass=\"interactions\" rev=\"1.21\" parent=\"/drugs/epirubicin-hydrochloride\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (epirubicin).</p>\n</sectiondiv>\n<sectiondiv>\n<p>Caution is necessary with concomitant use of cardiotoxic drugs, or drugs that reduce cardiac contractility.</p>\n<p>Concomitant use with trastuzumab is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If trastuzumab needs to be used, cardiac function should be monitored closely.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49696\" outputclass=\"sideEffects\" rev=\"1.24\" parent=\"/drugs/epirubicin-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">cardiotoxicity</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">hyperpigmentation of nails</ph>; <ph outputclass=\"sideEffect\">hyperpigmentation of oral mucosa</ph>; <ph outputclass=\"sideEffect\">hyperpigmentation of skin</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">red colouration of the urine</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Cardiotoxicity</p>\n<p>A maximum cumulative dose of 0.9&#8211;1&#8239;g/m<sup>2</sup> is recommended to help avoid cardiotoxicity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49867\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/epirubicin-hydrochloride\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49740\" outputclass=\"pregnancy\" parent=\"/drugs/epirubicin-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (carcinogenic in <i>animal</i> studies).</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49895\" outputclass=\"breastFeeding\" parent=\"/drugs/epirubicin-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49811\" outputclass=\"hepaticImpairment\" parent=\"/drugs/epirubicin-hydrochloride\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose according to bilirubin concentration&#8212;consult local treatment protocol for details.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49715\" outputclass=\"renalImpairment\" parent=\"/drugs/epirubicin-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Dose reduction may be necessary in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5315-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/epirubicin-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: solution for injection, solution for infusion</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76223\" title=\"Solution for injection\" namespace=\"/drugs/epirubicin-hydrochloride/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76230\" title=\"Solution for infusion\" namespace=\"/drugs/epirubicin-hydrochloride/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78515\" namespace=\"/treatment-summaries/bladder-instillations-and-urological-surgery\" title=\"Bladder instillations and urological surgery\" count=\"1\" rel=\"backlink\">Bladder instillations and urological surgery</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78537\" namespace=\"/treatment-summaries/cytotoxic-drugs\" title=\"Cytotoxic drugs\" count=\"2\" rel=\"backlink\">Cytotoxic drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78591\" namespace=\"/treatment-summaries/hormones-malignant-disease\" title=\"Hormones, malignant disease\" count=\"1\" rel=\"backlink\">Hormones, malignant disease</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1030\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antibiotics-cytotoxic/epirubicin\" title=\"Epirubicin\" count=\"1\" rel=\"link\">Epirubicin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76223\" namespace=\"/drugs/epirubicin-hydrochloride/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76230\" namespace=\"/drugs/epirubicin-hydrochloride/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5315",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/epirubicin-hydrochloride",
    "basename": "epirubicin-hydrochloride",
    "title": "EPIRUBICIN HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_1030",
            "label": "Epirubicin"
        }
    ],
    "vtmid": "349848009",
    "drugClassification": [
        "Anthracyclines"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of breast cancer",
                        "html": "Treatment of breast cancer"
                    },
                    {
                        "textContent": "Treatment and prophylaxis of certain forms of superficial bladder cancer",
                        "html": "Treatment and prophylaxis of certain forms of superficial bladder cancer"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion or intravesical instillation"
                    ],
                    "textContent": "By intravenous infusion or by intravesical instillation",
                    "html": "By intravenous infusion or by intravesical instillation"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Bladder inflammation or contraction (when used as a bladder instillation)",
                "html": "Bladder inflammation or contraction (when used as a bladder instillation)"
            },
            {
                "type": "contraindications",
                "textContent": "catheterisation difficulties (when used as a bladder instillation)",
                "html": "catheterisation difficulties (when used as a bladder instillation)"
            },
            {
                "type": "contraindications",
                "textContent": "haematuria (when used as a bladder instillation)",
                "html": "haematuria (when used as a bladder instillation)"
            },
            {
                "type": "contraindications",
                "textContent": "invasive tumours penetrating the bladder (when used as a bladder instillation)",
                "html": "invasive tumours penetrating the bladder (when used as a bladder instillation)"
            },
            {
                "type": "contraindications",
                "textContent": "myocardiopathy",
                "html": "myocardiopathy"
            },
            {
                "type": "contraindications",
                "textContent": "previous treatment with maximum cumulative doses of epirubicin or other anthracycline",
                "html": "previous treatment with maximum cumulative doses of epirubicin or other anthracycline"
            },
            {
                "type": "contraindications",
                "textContent": "recent myocardial infarction",
                "html": "recent myocardial infarction"
            },
            {
                "type": "contraindications",
                "textContent": "severe arrhythmia",
                "html": "severe arrhythmia"
            },
            {
                "type": "contraindications",
                "textContent": "severe myocardial insufficiency",
                "html": "severe myocardial insufficiency"
            },
            {
                "type": "contraindications",
                "textContent": "unstable angina",
                "html": "unstable angina"
            },
            {
                "type": "contraindications",
                "textContent": "urinary tract infections (when used as a bladder instillation)",
                "html": "urinary tract infections (when used as a bladder instillation)"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Caution in handling&#8212;irritant to tissues",
                "html": "Caution in handling&#8212;irritant to tissues"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (epirubicin).",
                "html": "<p>Appendix 1 (epirubicin).</p>"
            },
            {
                "type": "general",
                "textContent": "Caution is necessary with concomitant use of cardiotoxic drugs, or drugs that reduce cardiac contractility.\n\nConcomitant use with trastuzumab is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If trastuzumab needs to be used, cardiac function should be monitored closely.",
                "html": "<p>Caution is necessary with concomitant use of cardiotoxic drugs, or drugs that reduce cardiac contractility.</p><p>Concomitant use with trastuzumab is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If trastuzumab needs to be used, cardiac function should be monitored closely.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "cardiotoxicity",
                        "html": "cardiotoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperpigmentation of nails",
                        "html": "hyperpigmentation of nails",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperpigmentation of oral mucosa",
                        "html": "hyperpigmentation of oral mucosa",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperpigmentation of skin",
                        "html": "hyperpigmentation of skin",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "red colouration of the urine",
                        "html": "red colouration of the urine",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Cardiotoxicity",
                "textContent": "A maximum cumulative dose of 0.9&#8211;1 g/m2 is recommended to help avoid cardiotoxicity.",
                "html": "<p>A maximum cumulative dose of 0.9&#8211;1&#8239;g/m<sup>2</sup> is recommended to help avoid cardiotoxicity.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (carcinogenic in animal studies).\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (carcinogenic in <i>animal</i> studies).</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose according to bilirubin concentration&#8212;consult local treatment protocol for details.",
                "html": "<p>Reduce dose according to bilirubin concentration&#8212;consult local treatment protocol for details.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Dose reduction may be necessary in severe impairment.",
                "html": "<p>Dose reduction may be necessary in severe impairment.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "solution for injection",
                "solution for infusion"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76223",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76230",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78515",
                "label": "Bladder instillations and urological surgery",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78537",
                "label": "Cytotoxic drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78591",
                "label": "Hormones, malignant disease",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1030",
                "label": "Epirubicin",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76223",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76230",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}